top of page
In the context of the PRAISE e-cohort, we listed here scientific articles about OASI. This list is regularly updated.
Last update: January 29th, 2020
Search
Feb 1, 2020
Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing[...]
S. Jamal et al., 2020. Immune checkpoint inhibitors have revolutionized cancer therapy by blocking inhibitory pathways of the immune...
Jun 13, 2019
Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
Salem JE et al., 2019 Immune checkpoint inhibitors are broadly active treatments for cancer, but they can result in immune-related...
Jan 24, 2019
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with RA
Gottenberg JE et al., 2019 Objective To compare the effectiveness and safety of three non-tumour necrosis factor (TNF) α inhibitors...
Aug 20, 2018
Impact of Baseline Steroids on Efficacy of Programmed CellDeath-1 and Programmed Death-Ligand 1 ...
Purpose Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients...
Jun 28, 2018
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-Review From the Mela [...]
Kristina Buder-Bakhaya et al., 2018 Background: Immune checkpoint inhibition (ICI) with anti-CTLA-4 and/or anti-PD-1 antibodies is...
Mar 1, 2018
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer
K. Haratani et al., 2018. Importance Immune-related adverse events (irAEs) have been associated with the efficacy of PD-1 (programmed...
Feb 14, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint [...]
J.R Brahmer et al., 2018. Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of...
May 4, 2016
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros et al., 2016. Inhibition of immune checkpoints using anti-programmed cell death-1 (PD-1) or anti cytotoxic-T-lymphocyte-associ...
Feb 13, 2016
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 [...]
TK. Eigentler et al., 2016. PD-1 checkpoint inhibitors are associated with a specific spectrum of immune-related adverse events. This...
Feb 1, 2016
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
JM. Michot et al,. 2016. Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents...
Feb 1, 2016
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
DB Johnson et al., 2016 Importance Ipilimumab and other immune therapies are effective treatment options for patients with advanced...
Dec 28, 2015
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al., 2015. Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained...
Oct 7, 2015
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of IRAEs [...]
M. Freeman-Keller et al., 2016. To date, immunotherapy for cancer has generated significant response rates and prolonged survival,...
Jul 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al., 2015. BACKGROUND Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic...
Mar 7, 2014
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma [...]
M. Ryder et al., 2014. Novel immune checkpoint blockade with ipilimumab, an antibody blocking the cytotoxic T-lymphocyte antigen 4...
bottom of page